Global Community
Our community narratives are driven by numbers and valuation.
Community Investing Ideas
Global Weekly Picks
Are Blackrock Silver shares oversold?
Blackrock Silver [$BRC.v] / [$BKRRF] has a world-class, silver-heavy (with gold), high-grade project in Nevada, USA. Most silver/gold junior miners, including Blackrock Silver, have seen their share prices fall over 50% from 52-week highs.Read more
A transitional big-pharma giant holding a speculative premium driven by obesity hype, masking severe revenue erosion.
The "Amgen 2027 Bull Case" relies on a classic top-line fallacy: assuming that macro obesity market growth and FDA's CNPV (Commissioner’s National Priority Voucher) tailwinds will automatically trigger a re-rating. Here is the cold, data-driven reality: 1.Read more
Faces a brutal commercial dogfight against Pfizer’s entrenched monopoly and Alnylam’s silencers, compressing its safety margins
The "BridgeBio Commercial Bonanza" is priced for perfection, treating the upcoming Acoramidis launch as an automatic cash cow while ignoring a brutal multi-front commercial dogfight. Here is why the market is mispricing the structural hurdles for BBIO: 1.Read more
Ares Strategic Mining: $250M Pentagon Contract vs C$76M Market Cap
Ares Strategic Mining is trying to turn what it says is the only permitted fluorspar mine in the country into a working domestic supplier, backed by a major defense customer. The upside hinges on whether it can reliably process and deliver consistent, high-quality material, because key proof points on how much it can produce and at what cost are still missing.Read more
Accenture at $143 is a Coiled Spring
Wall Street is panicking over short-term IT budget freezes and the myth that AI will kill traditional consulting. They’ve severely mispriced a premier global monopoly, creating the ultimate contrarian entry point.Read more
An asymmetric deep-value biotech incubator trapped in a severe conglomerate discount despite recurring proof of multi-billion dollar asset.
The "PureTech Health Deep Value Re-rating Thesis" treats legendary track records like the $14B Karuna exit as a guarantee for near-term common equity growth, overlooking severe cross-border friction. Here is why the market keeps imposing a persistent, structural discount on PRTC: 1.Read more
burns cash despite four approved drugs, trapped by structural inefficiencies and gene-therapy scaling hurdles that thin safety margins.
The "Ultragenyx Turnaround Thesis" is trapped in a commercial illusion, mistaking a multi-product portfolio for financial stability while ignoring deep-rooted structural inefficiencies. Here is why the market is mispricing the friction inside RARE’s operational engine: 1.Read more
A little Prince. FBIO.
The "Fortress Biotech PRV Mirage" relies on superficial GAAP net income numbers, treating a one-time regulatory windfall as a permanent structural inflection. Here is why the market naturally maintains a holding-company discount on FBIO: 1.Read more
MSCI 04-2026
MSCI quietly sits behind a huge share of the world’s investment products by supplying the yardsticks many big institutions use to measure and build their funds. The key question is whether its hard-to-replace role and push into private markets can keep compounding—or whether any stumble could matter more than investors expect.Read more
